News Release: Innovative Medicines Canada Welcomes Pamela Fralick as New President

See original article here

Ottawa, December 1, 2016 – Innovative Medicines Canada is pleased to announce the appointment of Pamela Fralick as its new President, effective immediately.

Ms. Fralick comes to Innovative Medicines Canada as a proven healthcare leader, with a wealth of experience advancing critical healthcare initiatives and a deep understanding of public policy and organizational management. “We are extremely pleased to have Ms. Fralick lead our association at such an important time both for the country’s innovative pharmaceutical industry and in the evolution of the Canadian healthcare system,” said Michael Tremblay, Chair of the Board of Directors, Innovative Medicines Canada and President of Astellas Pharma Canada, Inc. “Ms. Fralick has had a unique opportunity to participate in many aspects of Canada’s healthcare system, and throughout her career has demonstrated a commitment to improving the lives and health outcomes of Canadians. We believe she is the right person to lead Innovative Medicines Canada as we work with our partners to build a more healthcare sustainable system.” As the former President and CEO of the Canadian Cancer Society, Ms. Fralick led a three-year process of intense transformation, resulting in significant improvements to the operational and governance structures of the organization. Prior to this, she spent five years as president and CEO of the Canadian Healthcare Association, a federation of provincial and territorial hospital and health organizations, as well as six years as CEO of the Canadian Physiotherapy Association. She was chair of the Health Action Lobby (HEAL) and co-chair of the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has also held senior positions with the Canadian Centre on Substance Abuse and Health Canada’s Alcohol and Other Drugs Unit. “As a healthcare professional dedicated to helping Canadians live longer and healthier lives, I am honoured  to represent a national association whose members are responsible for developing innovative medicines and vaccines that materially improve the quality of life for so many Canadians,” said Pamela Fralick, President, Innovative Medicines Canada. “I look forward to collaborating with all of our partners across the country to improve access to these lifesaving medicines.” Ms. Fralick has also been a senior volunteer with the Centre for Addiction and Mental Health, the University of Ottawa Institute of Mental Health Research, Triathlon Canada and the International Triathlon Union. She is currently on the boards of Outward Bound Canada (Chair) and the Canada Dance Festival (Past Chair). Ms. Fralick takes over from Elaine Campbell, who has been Interim President of Innovative Medicines Canada since June. -30- For further information: Sarah Dion-Marquis Media Relations Telephone: 613-769-6510 E-mail: sdmarquis@imc-mnc.ca   About Innovative Medicines Canada Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.  ]]>

Innovative Medicines Canada – Atlantic – Recognizing National Immunization Awareness Week in Atlantic Canada

April 27, 2016 Innovative Medicines Canada – Atlantic – Recognizing National Immunization Awareness Week in Atlantic Canada Released this morning: Championing immunization is everyone’s business HALIFAX, April 27, 2016 /CNW/ – On the occasion of National Immunization Awareness Week (April 24 to 30, 2016), which coincides with both World Immunization Week (a declaration by the World Health Organization) as well as Vaccination Week in the Americas (a declaration by the Pan American Health Organization), Innovative Medicines Canada is reminding Canadians that they can be champions in the fight against diseases by getting vaccinated. Organizations from around the world this week are working to increase awareness about the importance of immunization for all ages. “It’s our responsibility, as part of our Canadian community, to get the facts about vaccines,” said Russell Williams, President, Innovative Medicines Canada. “According to the World Health Organization, 2 to 3 million deaths are averted worldwide each year thanks to vaccines, but an additional 1.5 million deaths could be avoided. Our industry is focused on closing that immunization gap, and we commend the work of governments across Canada as they work towards this goal.” Since 2007, Atlantic Canada is home to the Canadian Center for Vaccinology (CCfV) located at the IWK Health Centre in Halifax, Nova Scotia. Established to develop, implement, and evaluate vaccine technologies and vaccines for infectious diseases that have a significant impact on Canadian and global health and to train experts in these fields. The creation of the CCfV is a collaboration of Dalhousie University, the IWK Health Centre, and Nova Scotia Health Authority. The CCfV expanded in 2009 to include the Sanofi Pasteur Vaccine Challenge unit / Clinical Research Unit, a first of its kind in Canada, is a leading edge global v! accine research centre. The funding made possible by Innovative Medicines Canada member Sanofi Pasteur. Today, more than 25 infectious diseases are vaccine-preventable – not only in children, but also in adolescents, adults and travelers. Recognized as one of the greatest achievements in public health, immunization is key to protecting Canadians and has saved more lives in Canada than any other health initiative in 50 years. However, the benefits of these innovations are limited by the degree to which the population actually gets immunized. ABOUT INNOVATIVE MEDICINES CANADA Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.   SOURCE Innovative Medicines Canada For further information: Sarah Douglas, Media Relations, Telephone: 613-883-7250, E-mail: sdouglas@imc-mnc.ca ]]>

Life Sciences offers solutions for growth in Nova Scotia after 2016-17 budget release

NEWS RELEASE HALIFAX, April 21, 2016 — On Tuesday the Nova Scotia government tabled its 2016-17 Budget with a surplus of $17.1 million and a commitment to work collaboratively with industries with big potential in the province. As part of the Budget address, the province called for a collaborative approach model to boost the economy. “This government understands that we cannot solve our economic problems alone. We need to work together to create a stronger economy, a stronger Nova Scotia,..” stated the- Hon. Randy Delorey, Minister of Finance as part of Budget 2016-2017 The life sciences industry in Nova Scotia has indicated it is ready to work with government and is poised as a growth facilitator for the province’s future economic and social prosperity. Generating nearly $300 million in revenues for the province and exporting up to 90% of products, the sector offers a strong and sustainable economic strategy. “With further support from the province for the life sciences community to develop their ideas, commercialize their technologies and build links within the region and internationally we will continue to be a wealth generator for the province,” said Scott Moffitt, Managing Director of BioNova, the life science industry association. The industry has also been fostering valuable collaborative relationships with national associations such as Innovative Medicines Canada to accelerate the development of local pharmaceutical companies, as evidenced by the recent signing of a memorandum of understanding to enhance Nova Scotia’s medical technology portfolio. In recent years, the local life sciences industry has also seen a significant increase in innovation and potential coming from Nova Scotia companies. Immunovaccine Inc. is a good example of this, with a greater than $60 million market cap and a new CEO focused on industry collaborations to continue down the path of growth. The $540 million acquisition of Nova Scotia-based Ocean Nutrition Canada by Royal DSM, a global life science and material sciences company, is another example of growth in the sector. “It’s easy to imagine what more growth in this sector could lead to for Nova Scotians. We look forward to building strong links with the Government of Nova Scotia to further innovation in Nova Scotia’s life sciences sector,” said Russell Williams, President of Innovative Medicines Canada. ABOUT BIONOVA BioNova is Nova Scotia’s life sciences industry association and sector development organization. BioNova leads and supports its members as we build a successful, self-sustaining life sciences industry in Nova Scotia. By promoting the industry and its successes, building relationships both inside and outside the province and creating networking and educational opportunities BioNova aims to accelerate the commercialization success of Nova Scotia’s life sciences businesses and organizations. ABOUT INNOVATIVE MEDICINES CANADA Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.   – 30 – For further information: Shana McRae Marketing & Communications Officer, BioNova Telephone: 902-421-5705 ext. 2 E-mail: smcrae@bionova.ca Sarah Douglas Media Relations, Innovative Medicines Canada Telephone: 613-883-7250 E-mail: sdouglas@imc-mnc.ca]]>

BioNova and Innovative Medicines Canada Collaborate on Nova Scotia Life Sciences Research

Halifax, April 19, 2016 – Today, BioNova and Innovative Medicines Canada announced the signing of a memorandum of understanding between the organizations to foster collaboration in Canada’s life sciences communities between the pharmaceutical sector and life sciences organizations in Nova Scotia. “This agreement will accelerate the development of pharmaceutical companies in Nova Scotia – supporting the local economy and giving Nova Scotian’s a voice for issues on a federal level,” said Scott Moffitt, Managing Director of BioNova. “We’re very pleased about this partnership and look forward to working closely with Innovative Medicines Canada.” This memorandum of understanding will allow BioNova and Innovative Medicines Canada to offer a joint membership to life sciences companies and associated stakeholders in Canada in an effort to enhance networking opportunities and develop partnerships that will lead to the discovery of the next generation of life-saving therapies. “Canada’s innovative pharmaceutical sector provides immense value to patients, to the healthcare system and to Canada’s economy as a whole,” said Russell Williams, President of Innovative Medicines Canada. “We look forward to promoting and stimulating this great, innovative work with BioNova to ensure that Nova Scotia’s life sciences economy can flourish in Canada to the benefit of all.”

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

About BioNova

BioNova is Nova Scotia’s life sciences industry association and sector development organization. BioNova leads and supports its members as we build a successful, self-sustaining life sciences industry in Nova Scotia. By promoting the industry and its successes, building relationships both inside and outside the province and creating networking and educational opportunities BioNova aims to accelerate the commercialization success of Nova Scotia’s life sciences businesses and organizations. – 30 –   For further information: Sarah Douglas Media Relations, Innovative Medicines Canada Telephone: 613-883-7250 E-mail: sdouglas@imc-mnc.ca   Shana McRae Marketing & Communications Officer, BioNova Telephone: 902-421-5705 ext. 2 E-mail: smcrae@bionova.ca  ]]>